ASND
Price
$198.87
Change
+$4.60 (+2.37%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
11.76B
72 days until earnings call
ZYME
Price
$14.00
Change
-$0.81 (-5.47%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.12B
Interact to see
Advertisement

ASND vs ZYME

Header iconASND vs ZYME Comparison
Open Charts ASND vs ZYMEBanner chart's image
Ascendis Pharma A/S
Price$198.87
Change+$4.60 (+2.37%)
Volume$14.62K
Capitalization11.76B
Zymeworks
Price$14.00
Change-$0.81 (-5.47%)
Volume$5.99K
Capitalization1.12B
ASND vs ZYME Comparison Chart in %
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. ZYME commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Hold and ZYME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ASND: $194.27 vs. ZYME: $14.81)
Brand notoriety: ASND and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 77% vs. ZYME: 68%
Market capitalization -- ASND: $11.76B vs. ZYME: $1.12B
ASND [@Biotechnology] is valued at $11.76B. ZYME’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than ASND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 6 bullish TA indicator(s).

  • ASND’s TA Score: 3 bullish, 6 bearish.
  • ZYME’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than ASND.

Price Growth

ASND (@Biotechnology) experienced а -0.02% price change this week, while ZYME (@Biotechnology) price change was -1.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ASND is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($11.8B) has a higher market cap than ZYME($1.12B). ASND YTD gains are higher at: 41.113 vs. ZYME (1.161). ZYME has higher annual earnings (EBITDA): -69.77M vs. ASND (-161.68M). ASND has more cash in the bank: 518M vs. ZYME (281M). ZYME has less debt than ASND: ZYME (18.7M) vs ASND (847M). ASND has higher revenues than ZYME: ASND (491M) vs ZYME (123M).
ASNDZYMEASND / ZYME
Capitalization11.8B1.12B1,052%
EBITDA-161.68M-69.77M232%
Gain YTD41.1131.1613,541%
P/E RatioN/AN/A-
Revenue491M123M399%
Total Cash518M281M184%
Total Debt847M18.7M4,529%
FUNDAMENTALS RATINGS
ASND vs ZYME: Fundamental Ratings
ASND
ZYME
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4243
P/E GROWTH RATING
1..100
10063
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for ASND (89) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that ASND’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ASND (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ASND’s over the last 12 months.

ASND's Price Growth Rating (42) in the Biotechnology industry is in the same range as ZYME (43) in the Pharmaceuticals Major industry. This means that ASND’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's P/E Growth Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for ASND (100) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than ASND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDZYME
RSI
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 5 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
73%
Bearish Trend 5 days ago
78%
Momentum
ODDS (%)
Bearish Trend 5 days ago
75%
Bullish Trend 5 days ago
76%
MACD
ODDS (%)
Bearish Trend 5 days ago
77%
Bullish Trend 5 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 5 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
73%
Bullish Trend 5 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
74%
Aroon
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JGH13.580.10
+0.74%
NUVEEN GLOBAL HIGH Income FUND
PFRL50.420.07
+0.13%
PGIM Floating Rate Income ETF
IMAY28.79N/A
N/A
Innovator Intl Dev Pwr Bffr ETF - May
HIYS25.65-0.02
-0.06%
Invesco High Yield Select ETF
BULZ191.59-10.04
-4.98%
MicroSectors™ Slct FANG Inn 3X Lvgd ETNs

ASND and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
+0.19%
NUVL - ASND
39%
Loosely correlated
+0.74%
ZNTL - ASND
37%
Loosely correlated
-3.98%
ZYME - ASND
32%
Poorly correlated
-0.20%
KYMR - ASND
31%
Poorly correlated
-1.32%
BMRN - ASND
31%
Poorly correlated
+1.02%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with CRNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-0.20%
CRNX - ZYME
49%
Loosely correlated
+1.11%
NRIX - ZYME
49%
Loosely correlated
-0.74%
ABEO - ZYME
49%
Loosely correlated
-0.73%
AGIO - ZYME
48%
Loosely correlated
-1.23%
IDYA - ZYME
47%
Loosely correlated
-1.52%
More